Since all the parametric 90% confidence intervals for the log-transformed main variables of glimepiride were within the 0.80 and 1.25 interval, accepted as the definition of bioequivalence, and the differences in times to reach maximal concentration also did not reach statistical significance, studied tablets were considered bioequivalent.

In vitro and in vivo studies were conducted to evaluate the efficacy of organozeolite (Min-a-Zel Plus®) to alleviate the toxic effects of zearalenone (ZEN) in lambs. Min-a-Zel Plus® was able to bind >90% of ZEN in vitro at pH 3, 7 and 9. For in vivo studies, sixty four lambs were divided in to four groups which included: I - control group - basal diet containing neither Min-a-Zel Plus® nor zearalenone; II - basal diet supplemented with 8.3 mg ZEN/kg diet; III - basal diet supplemented with 8.3 mg ZEN/kg and 0.2% Min-a-Zel Plus®; IV - basal diet supplemented with 8.3 mg ZEN/kg and 0.5% Min-a-Zel Plus®. The Min-a-Zel Plus® supplement dramatically reduced the content of ZEN in liver, kidneys and muscles. The lower amount (0.2%) reduced the content of ZEN in all samples, but ZEN was still present in the organs. Addition of 0.5% Min-a-Zel Plus® eliminated ZEN from all organs, totally. These results indicate that Min-a-Zel Plus® is effective in preventing the toxic effects of ZEN, which may be present in lamb rations

The current clinical research on pharmacokinetics of methylprednisolone was performed on male pigs to whom was administered either intravenously or locally, via iontophoresis. Equal doses of methylprednisolone sodium succinate (MPSS) were applied, i.e. 40 mg it total per animal. In all pigs artificial inflammation of knee and elbow joints was provoked four days prior to the treatment. Four hours after the application of methylprednisolone tissue samples (both synovial fluid and hyaline cartilage) were obtained from the inflamed joints and subjected to analysis. The quantification of the drug was performed by HPLC technique. The results indicated high quantities of methylprednisolone both in the synovial fluid and hyaline cartilage, the concentrations being significantly higher in animals after iontophoretic application (17.15±3.11 and 12.70±2.19 μg/g, respectively) in comparison with the animals treated intravenously (0.33±0.11 and 0.21±0.06 μg/g, respectively). Thus, iontophoresis was proved a highly advisable clinical means of application of methylprednisolone, especially having in mind the possibility of avoiding systemic adverse effects which are present after parenteral drug administration. In addition, it enables higher therapeutic concentrations of MPSS to be obtained both in the synovial fluid and in the hyaline cartilage of the treated inflamed joints

No abstract

No abstract